Medivir to present at Swiss Nordic Bio in Zürich on March 7

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company will participate at the Swiss Nordic Bio conference on March 7, 2024.

 
CEO Jens Lindberg will present Medivir with focus on data from the ongoing phase 1b/2a clinical study with fostroxacitabine bralpamide (fostrox) and how these data enable an acceleration of fostrox's development program.

Swiss Nordic Bio aims to bring together biotech, pharma and life science investors from Switzerland and the Nordic region. In addition to the presentation, the company will also conduct a number of 1-1 meetings with potential investors and partners.

After the meeting, the presentation will also be available on Medivir's website www.medivir.se.

For additional information, please contact
Magnus Christensen, CFO, Medivir AB
Telephone: +46 8 5468 3100
E-mail: [email protected]

Medivir in brief

Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Medivir is focusing on the development of fostroxacitabine bralpamide (fostrox), a pro-drug designed to selectively treat liver cancer and to minimize side effects. Collaborations and partnerships are important parts of Medivir’s business model, and the drug development is conducted either by Medivir or in partnership. Medivir’s share (ticker: MVIR) is listed on Nasdaq Stockholm’s Small Cap list. www.medivir.com.